Biologics in Asthma

Author(s):

Nicole Chase, MD, FAAP, FACAAI, FAAAAI,S. Shahzad Mustafa, MD

The expert panel discusses the use of biologics in treating asthma, explaining their mechanisms of action, differences, and target populations, while also examining trends in long-term efficacy and safety for patients with severe or uncontrolled asthma.

EP: 1.External Factors and Seasonality of Asthma

EP: 2.Endotypes and Phenotypes in Asthma

EP: 3.Type 2 Inflammation and Biomarkers in Asthma

EP: 4.Moderate/Severe/Uncontrolled Asthma Classification

EP: 5.Thinking About Endotypes when Managing Asthma

EP: 6.Use of Oral Corticosteroids in Asthma

EP: 7.High Oral Corticosteroid Dose and Exposure in Asthma

EP: 8.Oral Corticosteroid Overuse and Uncontrolled Asthma

EP: 9.Biomarkers and Eosinophil Levels in Severe or Uncontrolled Asthma

Now Viewing

EP: 10.Biologics in Asthma

EP: 11.GINA Guidelines and Biologics for Treatment of Asthma

EP: 12.Use of Biologics for Asthma in Patients with Allergies

EP: 13.Treatment of Asthma in Pediatric Patients

EP: 14.Atopic March in Pediatric Patients

EP: 15.Use of Biologics in Pediatric Patients and Conversations with Parents

EP: 16.Biologic Options in Pediatric Asthma

EP: 17.Advice for Clinicians Managing Asthma

Video content above is prompted by the following question(s):

A number of biologics are now available for treatment of asthma. Please provide an overview of how they work and in which patient populations they are most effective in.
What trends are seen in long-term efficacy and safety of biologics in patients with severe or uncontrolled asthma?